Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
- Evaluated articles (Rapid Reviews Infectious Diseases)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2020.11.01.362319: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Written informed consent was obtained from all donors. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources After incubation, PBMCs were harvested and washed before adding fixable red viability dye (Thermo Fisher Scientific) and cell surface antibodies anti-CD3-PerCP5.5 (Biolegend, San Diego, CA, US), anti-CD4-APC-Cy7(Biolegend), anti-CD8-BV510 (Biolegend), anti-PD-1-Pacific Blue (Biolegend) and anti-CXCR5-APC (Biolegend). anti-CD3-PerCP5.5suggested: Noneanti-CD4-APC-Cy7suggested: (BD Biosciences Cat# custom null, RRID:AB_10015166)anti-CD8-BV510sugge…SciScore for 10.1101/2020.11.01.362319: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Written informed consent was obtained from all donors. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources After incubation, PBMCs were harvested and washed before adding fixable red viability dye (Thermo Fisher Scientific) and cell surface antibodies anti-CD3-PerCP5.5 (Biolegend, San Diego, CA, US), anti-CD4-APC-Cy7(Biolegend), anti-CD8-BV510 (Biolegend), anti-PD-1-Pacific Blue (Biolegend) and anti-CXCR5-APC (Biolegend). anti-CD3-PerCP5.5suggested: Noneanti-CD4-APC-Cy7suggested: (BD Biosciences Cat# custom null, RRID:AB_10015166)anti-CD8-BV510suggested: Noneanti-PD-1-Pacific Blue (Biolegend)suggested: Noneanti-CXCR5-APCsuggested: NoneFollowing incubation, the fixed cells were permeabilized with 0.1% Triton–X 100 at (Sigma Aldrich) on ice for 30min, washed with PBS and stained at 4°C for 50 mins with the intracellular antibodies, anti-TNF-α-FITC (Biolegend), anti-IFN-g-AF700 (Biolegend), anti-IL-2-PE-Cy7 (Biolegend) and anti-IL-4-PE (Biolegend). anti-TNF-α-FITCsuggested: (Miltenyi Biotec Cat# 130-109-765, RRID:AB_2654206)anti-IFN-g-AF700suggested: Noneanti-IL-2-PE-Cy7suggested: Noneanti-IL-4-PEsuggested: NoneSoftware and Algorithms Sentences Resources Cut off levels for positivity were set at >0.8 for the Abbott (N), >5 for RBD (S) and >1.1 for EuroImmun (S) assay as described earlier(32). Abbottsuggested: (Abbott, RRID:SCR_010477)10 software (FlowJo LLC, Ashland, Oregon, US). FlowJosuggested: (FlowJo, RRID:SCR_008520)Pestle and SPICE software (version 6) was used to determine the frequency of different cytokine response patterns based on all possible combinations (33). SPICEsuggested: (SPICE, RRID:SCR_016603)Statistical analysis: Statistical analysis was performed with GraphPad Prism 8. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 24. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
Sulggi Lee
Review 2: "Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection"
This reliable study finds that SARS-CoV-2 infection generates substantial immune memory. Antibody levels does not wane fast and T cell immune responses are readily detected 6 months after primary infection and correlate with disease severity.
-
Martin Tolstrup
Review 1: "Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection"
This reliable study finds that SARS-CoV-2 infection generates substantial immune memory. Antibody levels does not wane fast and T cell immune responses are readily detected 6 months after primary infection and correlate with disease severity.
-
Strength of evidence
Reviewers: Martin Tolstrup (Aarhus University) | 📗📗📗📗◻️
Sulggi Lee (UCSF) | 📗📗📗📗◻️ -
-
SciScore for 10.1101/2020.11.01.362319: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Written informed consent was obtained from all donors. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources After incubation, PBMCs were harvested and washed before adding fixable red viability dye (Thermo Fisher Scientific) and cell surface antibodies anti-CD3-PerCP5.5 (Biolegend, San Diego, CA, US), anti-CD4-APC-Cy7(Biolegend), anti-CD8-BV510 (Biolegend), anti-PD-1- Pacific Blue (Biolegend) and anti-CXCR5-APC (Biolegend). …anti-CD3-PerCP5.5suggested: NoneSciScore for 10.1101/2020.11.01.362319: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Written informed consent was obtained from all donors. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources After incubation, PBMCs were harvested and washed before adding fixable red viability dye (Thermo Fisher Scientific) and cell surface antibodies anti-CD3-PerCP5.5 (Biolegend, San Diego, CA, US), anti-CD4-APC-Cy7(Biolegend), anti-CD8-BV510 (Biolegend), anti-PD-1- Pacific Blue (Biolegend) and anti-CXCR5-APC (Biolegend). anti-CD3-PerCP5.5suggested: Noneanti-CD4-APC-Cy7suggested: (BD Biosciences Cat# custom null, RRID:AB_10015166)anti-CD8-BV510suggested: Noneanti-PD-1-suggested: Noneanti-CXCR5-APCsuggested: NoneFollowing incubation, the fixed cells were permeabilized with 0.1% Triton–X 100 at (Sigma Aldrich) on ice for 30min, washed with PBS and stained at 4°C for 50 mins with the intracellular antibodies, anti-TNF-α-FITC (Biolegend), anti-IFN-g-AF700 (Biolegend), anti-IL-2PE-Cy7 (Biolegend) and anti-IL-4-PE (Biolegend). anti-TNF-α-FITCsuggested: (Miltenyi Biotec Cat# 130-109-718, RRID:AB_2654207)anti-IFN-g-AF700suggested: Noneanti-IL-2PE-Cy7suggested: Noneanti-IL-4-PEsuggested: NoneSoftware and Algorithms Sentences Resources All donors were SARS-CoV-2 seropositive using either the Euroimmun, RBD or Abbott test. Abbottsuggested: (Abbott, RRID:SCR_010477)10 software (FlowJo LLC, Ashland, Oregon, US). FlowJosuggested: (FlowJo, RRID:SCR_008520)Pestle and SPICE software (version 6) was used to determine the frequency of different cytokine response patterns based on all possible combinations (33). SPICEsuggested: (SPICE, RRID:SCR_016603)Statistical analysis Statistical analysis was performed with GraphPad Prism 8. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap used on page 24. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
-
